VSNL1 and non-small cell lung carcinoma: VILIP-1 expression in NSCLC patients (SCC plus adenocarcinoma cases, n = 81) surviving for more than 5 years was significantly higher than in those patients that survived for less than 5 years (p<0.0001) Further, after adjusting for tumor stage (p<0.006), grade (p<0.400) and histology (p<0.032), VILIP1 remained a significant predictor of time to death (p<0.006).